Author: John Pinching

Early‑stage study to assess safety and efficacy signals

Biosimilar launch strengthens Teva’s oncology portfolio

Deal adds bioanalytical expertise in Australia

First pharmacological option for early intervention

Approval gives patients access to new targeted option